Do BRAF inhibitors select for populations with different disease progression kinetics?

Ipilimumab, an anti-CTLA-4 monoclonal antibody, has been shown to improve overall survival in patients with metastatic melanoma. Preliminary data suggest that patients who fail BRAF inhibitor treatment experience a very rapid progression of disease. Such selectivity for more rapid disease progressio...

Full description

Saved in:
Bibliographic Details
Main Authors: Ascierto, Paolo Antonio, Simeone, Ester, Grimaldi, Antonio Maria, Curvietto, Marcello, Esposito, Assunta, Palmieri, Giuseppe, Mozzillo, Nicola
Format: Artigo
Language:Inglês
Published: BioMed Central 2013
Subjects:
Commentary
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3599508/
https://ncbi.nlm.nih.gov/pubmed/23497384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-11-61
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items